SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting Mpro (IC50 of 30 nM)[1][2].

SDZ 224-015 (0.3-300 μg/kg) potently reduces carrageenin-induced paw oedema[2].

SDZ 224-015 (0.2-5 mg/kg, p.o.) displays analgesic activity in the Randall-Selitto yeast-inflamed paw pressure test, significant at a dose of 1 mg/kg[2].

161511-45-1

C30H35Cl2N3O9

652.52

SDZ 224-015

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years